|Mr. William J. Rieflin J.D.||Exec. Chairman of Directors||N/A||N/A||1960|
|Dr. David J. Woodhouse||CEO & Director||615.75k||N/A||1971|
|Dr. Jin-Long Chen||Founder, Chief Scientific Officer & Director||625.75k||N/A||1963|
|Dr. Aetna Wun Trombley||Consultant||550.75k||N/A||1980|
|Ms. Siobhan Nolan Mangini||CFO and Principal Financial & Accounting Officer||N/A||N/A||1981|
NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include Aldafermin, an engineered variant of the FGF19 human hormone in Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b clinical trial for use in the treatment of type 2 diabetes and NASH; and NGM395, which is engineered variant of the GDF15 human hormone for use in the treatment of metabolic syndrome. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in Phase 1 clinical trials to decrease levels of a protein implicated in the dry form of AMD. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
NGM Biopharmaceuticals, Inc.’s ISS Governance QualityScore as of December 9, 2019 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 8; Compensation: 9.